Researchers have designed a non-invasive and inexpensive chip-based optical biosensor with increased sensitivity to detect the presence and progression of cancerous tumors. The cancer protein biomarker S100A4 was detected at concentrations of 300 picomolar in a synthetic urine sample.
A study carried out by researchers based at the University of Cambridge (UK) and biotechnology company SomaLogic (CO, USA) has demonstrated that large-scale measurements of proteins in a single blood test could predict risk factors for a range of diseases.
Researchers from Dyno Therapeutics (MA, USA) and Harvard University (MA, USA) have reported a comprehensive machine-guided approach to produce improved adeno-associated virus capsids for gene therapy delivery.
Read the Bioanalysis Zone team’s top five take away messages from the 12th EBF Open Symposium, from automation to patient-centric sampling in this conference report.
TriAltus Bioscience (AL, USA) has announced the launch of a new affinity chromatography resin for the cl7/im7 protein purification system, with double the binding capacity of the original resin for the single-step protein purification system.
Novel microfluidic impedance cytometry device: simultaneous measurement of single-cell lateral position and biophysical properties
A research team from Singapore University of Technology and Design (Singapore) has developed a microfluidic impedance flow cytometry device that could be capable of simultaneously measuring the lateral position and biophysical properties of single cells.
Researchers based at the University of Toronto (ON, CA) have developed a microfluidic device that could be used to separate malignant plasma cells from healthy red blood cells. The device could have the potential to detect and monitor blood cancer.
American biotechnology product development company, Thermo Fisher Scientific (MA, USA), has announced the official opening of a Customer Solution Center in Shanghai, China.
Researchers from the University of Texas Southwestern Medical Center (TX, USA) have identified a biomarker blood test that could identify individuals with early-stage heart disease in need of treatment.
Advancing novel biomarker identification: Thermo Fisher Scientific collaborate with Owlstone Medical
Thermo Fisher Scientific (MA, USA) have announced a collaborative partnership with Owlstone Medical (Cambridge, UK). The partnership will work towards the advancement of early cancer and disease diagnosis through the discovery and validation of novel biomarkers.